Detalhe da pesquisa
1.
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.
Future Oncol
; 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38357801
2.
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
Br J Cancer
; 128(1): 30-41, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36335217
3.
Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
Br J Cancer
; 128(2): 400, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36697966
4.
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer.
J Clin Oncol
; 41(21): 3700-3711, 2023 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37270692
5.
Synthesis, SAR and biological evaluation of 1,6-disubstituted-1H-pyrazolo[3,4-d]pyrimidines as dual inhibitors of Aurora kinases and CDK1.
Bioorg Med Chem Lett
; 22(5): 2070-4, 2012 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22326168
6.
Structure-based design of 2,6,7-trisubstituted-7H-pyrrolo[2,3-d]pyrimidines as Aurora kinases inhibitors.
Bioorg Med Chem Lett
; 22(12): 4033-7, 2012 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22607669
7.
A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer.
Expert Opin Investig Drugs
; 31(7): 747-757, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35657653
8.
Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery.
Bioorg Med Chem Lett
; 21(10): 3078-83, 2011 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21459573
9.
A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.
Target Oncol
; 12(6): 775-785, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-29067643
10.
Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors.
Clin Cancer Res
; 23(18): 5349-5357, 2017 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28634283
11.
Peginterferon Beta-1a Shows Antitumor Activity as a Single Agent and Enhances Efficacy of Standard of Care Cancer Therapeutics in Human Melanoma, Breast, Renal, and Colon Xenograft Models.
J Interferon Cytokine Res
; 37(1): 20-31, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27835061
12.
Identification of a Novel Allosteric Inhibitory Site on Tryptophan Hydroxylase 1 Enabling Unprecedented Selectivity Over all Related Hydroxylases.
Front Pharmacol
; 8: 240, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28529483
13.
EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor.
Cancer Res
; 76(6): 1591-602, 2016 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26825170
14.
Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines.
Blood
; 111(3): 1594-602, 2008 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18032710